Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk Ventilation 50% ICU admission 21% Combined NIV/ICU/vent.. 15% primary c19early.org/o Cecconi et al. Colchicine for COVID-19 RCT LATE TREATMENT Favors colchicine Favors control
Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial
Cecconi et al., Scientific Reports, doi:10.1038/s41598-022-13424-6
2 Jun 2022    Source   PDF   Share   Tweet
RCT 240 hospitalized patients with COVID-19 pneumonia, mean 9 days from the onset of symptoms, showing no significant differences with colchicine treatment. EudraCT 2020-001841-38.
Although the 29% lower mortality is not statistically significant, it is consistent with the significant 37% lower mortality [24‑47%] from meta analysis of the 33 mortality results to date.
risk of death, 29.4% lower, RR 0.71, p = 0.62, treatment 7 of 119 (5.9%), control 10 of 120 (8.3%), NNT 41.
risk of mechanical ventilation, 49.6% lower, RR 0.50, p = 0.29, treatment 5 of 119 (4.2%), control 10 of 120 (8.3%), NNT 24.
risk of ICU admission, 20.8% lower, RR 0.79, p = 0.67, treatment 11 of 119 (9.2%), control 14 of 120 (11.7%), NNT 41.
combined NIV/ICU/ventilation/death, 15.3% lower, RR 0.85, p = 0.62, treatment 21 of 119 (17.6%), control 25 of 120 (20.8%), NNT 31, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cecconi et al., 2 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, mean age 65.0, 31 authors, study period August 2020 - March 2021, average treatment delay 9.0 days, dosage 1mg day 1, 0.5mg days 2-5.
Contact: albertocecconi@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit